Hims & Hers CEO Andrew Dudum on telehealth's next act: personalized diagnostics, compounding, and $2B+ revenue

Summary

Andrew Dudum, CEO of Hims & Hers, is positioning the company's next phase around vertically integrated, personalized preventive care, anchoring it to a diagnostics and compounding infrastructure that most consumer health platforms cannot replicate at scale.

Diagnostics as a Loss Leader

Hims & Hers has launched a lab testing product priced at $1.99 for a base panel and $4.99 for an advanced panel, covering roughly 120 biomarkers. Dudum frames this as intentionally underpriced. His stated three-year target is to bundle testing into the platform for around $30 a month, and eventually offer it free to any active Hims & Hers subscriber. The logic is straightforward: biomarker data sharpens clinical decision-making, extends patient relationships over 5 to 15 years, and drives higher-value compounded prescription revenue downstream.

Dudum is unambiguous that standalone lab margins are heading to zero. Companies whose core business is diagnostics, including Quest Diagnostics and LabCorp, each valued at roughly $10 to $15 billion, face structural pressure as vertically integrated platforms absorb testing costs as customer acquisition spend rather than a revenue line.

Compounding at Scale

Hims & Hers operates 1 million square feet of pharmacy compounding capacity in the US, manufacturing a significant portion of its own medications. The model combines supplements (zinc, ashwagandha, magnesium), branded generics (statins, finasteride, minoxidil), and GLP-1 or GIP compounds into single personalized formulations delivered for roughly $30 to $40 a month. Dudum draws a direct parallel to concierge medicine, where similar personalization previously required spending $50,000 a year.

On regulatory risk, Dudum points to governance credentials: the company's chief medical officer previously held that role at Walgreens, and a board member who chairs the risk committee spent a decade writing compounding legislation at the FDA. He acknowledges ongoing friction with regulators and branded pharma but signals a long-term partnership model is likely, citing Hims & Hers' claim to be the largest direct-to-consumer therapeutics distribution platform in the US.

Hims & Hers has also taken an investment position in Grail, whose blood test claims to detect over 100 cancer types as early as stage one, signaling appetite for third-party diagnostic partnerships alongside internal compounding.

GLP-1 Market Outlook

Dudum expects the GLP-1 and GIP category to commoditize rapidly. Key catalysts he flags include Ntera's deal with Pfizer and Novo Nordisk, Kylera's recently closed growth round behind a GLP/GIP candidate it claims is at par or superior to Tirzepatide, Viking Therapeutics entering the market around 2029 or 2030, and Ozempic going generic around 2030 to 2031. At that point he estimates manufacturing cost per vial could fall to roughly $10.

Hims & Hers has already moved GLP-1 pricing from $1,500 a month at launch to approximately $150 today. Dudum's three-year projection puts leading GLP-1 treatments at around $50 a month, at which point he expects the market to shift decisively to cash pay via HSA and FSA, bypassing insurance entirely and unlocking a materially larger addressable population.

At-Home Diagnostics and the Theranos Question

Dudum believes the real addressable opportunity Theranos identified was eliminating the friction of in-office phlebotomy, not minimizing blood volume. He argues needle phobia and the logistics of scheduling clinic visits suppress testing rates far more than discomfort with the draw itself. He describes active internal work on at-home diagnostic devices, projecting a commercially available product within one to two years that uses capillary or interstitial fluid sampling, similar to a CGM, at an estimated cost of around $10 per test.

Unit Economics and Capital Allocation

Dudum describes a target healthcare membership priced at roughly $500 a year, framed as an alternative to high-deductible insurance plans that carry $2,000 deductibles and deliver little practical benefit to most holders. The company trades with a high-vote share structure, which Dudum credits with enabling longer investment horizons, noting the stock has ranged from a low he describes as $2.87 to a high of $70 during the post-SPAC correction period. The segment title references $2 billion-plus in revenue as a near-term benchmark for the platform.

Quality Risk in Compounded Peptides

On sourcing risks in the grey-market peptide space, Dudum points to certificates of analysis from independent third-party labs as the minimum verification standard. Hims & Hers provides these certificates to customers for all compounded products. He warns that a significant portion of peptides available online are labelled 'not for human use' as a regulatory workaround and carry meaningful contamination and dosing risks.